|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
06955 BOAN BIOTECH
Nominal 
6.850 +0.630 (+10.129%) | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | -- | -- | 726,316 | 618,129 | 515,960 | 158,704 |
| Cost of Sales | -- | -- | (183,663) | (209,161) | (161,730) | (52,190) |
| Gross Profit | -- | -- | 542,653 | 408,968 | 354,230 | 106,514 |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | -- | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | -- | -- | 73,189 | (119,377) | (331,749) | (225,417) | |
| Taxation | -- | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | -- | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 7,144 | -90.239% | 73,189 | (119,377) | (331,749) | (225,417) | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | -- | -- | 32,246 | 12,928 | 7,839 | 2,498 |
| Depreciation & Amortisation | -- | -- | 72,905 | 82,766 | 72,835 | 50,009 |
| Directors' Emoluments | -- | -- | 17,323 | 19,880 | 17,897 | 19,321 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 1.000 | -92.857% | 14.000 | -23.000 | -67.000 | -47.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | -- |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (0.220) | (0.036) | (0.405) | (0.515) |
| NBV per share ($) | -- | -- | 3.068 | 2.592 | 2.785 | -- |
| Remarks: | Real time quote last updated: 01/04/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 7,144 |
| %Change | -90.239% |
| EPS / (LPS) | RMB 0.010 |
| NBV Per Share (¥) | RMB -- |